Clinical Trial Update: A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study) [Phase 4]

View source ↗

Summary

Phase 4 study evaluating rFVIIIFc for immune tolerance induction in severe Hemophilia A patients with inhibitors; study completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia with Inhibitors

Drugs mentioned

• rFVIIIFc (recombinant factor VIII Fc fusion protein)

Snippet

Sponsor: Bioverativ, a Sanofi company | Conditions: Hemophilia A With Inhibitors | Phase 4 | Status: COMPLETED | Results posted: 2021-07-07